Table of Contents
The Impact of Genomics on Drug Discovery
Functional Genomics and Pharmacology - Agenda from Last Time -
Drug Discovery in the Post-Genomics Era: Part II - Agenda for Today -
Causative Approaches for Target Validation - “Reverse Genetics” -
Table 1. A comparison of different experimental approaches for modulating the function of cell signaling molecules
Mouse Transgenic and Gene Knockout Models
Additional Genetic Models for Functional Genomics
Genetic Models for Functional Genomics - Limitations -
Antisense Technology is Based on Simple “Watson-Crick” Hybridization Mechanisms
Watson-Crick Binding of Antisense Inhibitor to RNA
History Lesson
What were the initial major hurdles for antisense technology?
Antisense Mechanisms of Action
Medicinal Chemistry of Antisense Oligonucleotides
Antisense Specificity and Breadth - RNase H Dependent Mechanism -
Antisense Specificity and Versatility In Vivo - Intravenous Administration -
Antisense Technology for Functional Genomics
RNA Interference: A New Functional Genomics Tool
RNA Interference: A New Functional Genomics Tool
A Model for RNA Interference
New Approaches to Drug Discovery - Why the need? -
483
Small Molecule Drugs - “Drugable” vs “Non-Drugable” Protein Targets -
High-Throughput Screening for Drug Discovery - I
High-Throughput Screening for Drug Discovery - II
High-Throughput Screening for Drug Discovery - III
Monoclonal Antibody Therapy - I
Hybridoma Technology
Monoclonal Antibody Therapy - II
Monoclonal Antibody Therapy - III
Monoclonal Antibody Therapy - Successes I
Monoclonal Antibody Therapy: Successes II
Monoclonal Antibody Therapy: Successes III - Cancer Con’t. -
Protein Therapeutics - I
Protein Therapeutics - II
PPT Slide
Properties of Modified Insulins
Protein Therapeutics - III - New Drugs on the Horizon Based on Genomics -
Antisense Technology is Based on Simple “Watson-Crick” Hybridization Mechanisms
Critical Factors to be Considered for Optimizing Antisense Efficacy
Antisense Drug Discovery (Therapeutics) - Shortening the Timelines between Concept and Clinical Trials -
Antisense Drug Pipeline: Isis Pharmaceuticals
PKC Signaling
Isozyme-specific Reduction in PKC-a mRNA and Protein Expression by ISIS 3521
Activity of ISIS 3521 Against Calu-1 (lung) Human Tumor Xenograft
ISIS 3521 a Potent Inhibitor of PKC-_ in Non-Small Cell Lung Cancer:
Evidence Supporting PTP-1B as a Validated Therapeutic Target for Type 2 Diabetes
Evidence Supporting PTP-1B as a Validated Therapeutic Target for Type 2 Diabetes
Phylogenetic Tree of Protein Tyrosine Phosphatases - R. Hooft van Huijsduijnen / Gene 225 (1998) 1-8 -
Specific Inhibition of PTP-1B Expression in HEPG2 Cells
Dose-Dependent Lowering of Blood Glucose Levels in Diabetic Mice (db/db) Following PTP-1B Antisense Drug
ISIS 113715 / L-888, 728 (PTP-1B Antisense): A Novel Therapeutic Agent to Treat Type 2 Diabetes
Antisense Technology and the Future: Remaining Hurdles
|